New Delhi|H Live
Delhi High Court granted an interim stay on five major healthcare brands on Wednesday.
Procter & Gamble and Abbott will resume sales of their popular medicines ‘Vicks Action 500 Extra’ and cough syrup ‘Phensedyl’, respectively after Delhi High Court stayed government’s ban on sale of their certain combination drugs.
Several companies had approached the court challenging a decision by the Health Ministry to ban over 340 fixed dose combination drugs as a result of which many popular medicines have been affected.
“The company would resume manufacture and sale of Vicks Action 500 Extra,” P&G said in a statement a day after getting an interim relief from the court on the matter.
According to industry sources, Abbott has also resumed sales of its cough syrup Phensedyl following the court order.
Pfizer, which was the first to announce stopping of sales of its cough syrup Corex, refused to comment on whether it has resumed sales of the medicine after getting relief from the court.
Companies including, Pfizer, Abbott Healthcare, Macleods Pharmaceuticals and Procter & Gamble, Glenmark and Reckitt Benckiser have received interim relief from the Court which stayed till March 21 the ban imposed by the government on sale of some of their fixed dose combination (FDC) medicines.
In a gazette notification on March 10, the government had, among others, banned manufacture, sale and distribution of fixed does combination of chlopheniramine maleate plus codiene syrup which is used in the cough syrups.
The Delhi High Court granted an interim injunction to drugmaker Abbott against a government move to ban Phensedyl, among most selling syrups in our country.
About Rs. 252 crore is the annual sales of Phensedyl in country according to market research agency Pharma Trac.
